Prime Therapeutics Companies earn URAC re-accreditation in Pharmacy Benefit Management

Designation demonstrates highest level of commitment to quality health care

April 13, 2023

EAGAN, Minn. – April 13, 2023Prime Therapeutics LLC (Prime) is proud to announce that its companies, Magellan Rx Management, LLC  and Magellan Pharmacy Solutions, Inc., (Magellan Rx) have earned URAC re-accreditation for Pharmacy Benefit Management. URAC is the independent leader in promoting health care quality by setting high standards for clinical practice, consumer protections, performance measurement, operations infrastructure and risk management. By achieving this status, Magellan Rx demonstrates commitment to quality care, enhanced processes, patient safety and improved outcomes.

On Dec. 3, 2022, Prime finalized the acquisition of Magellan Rx, the pharmacy division of Magellan Health, from Centene Corporation. The agreement unites Prime’s strong foundation of pharmacy benefit management (PBM) capabilities with Magellan Rx’s industry-leading total specialty drug management expertise to create a diversified pharmacy solutions organization serving commercial markets and government programs.

“Retaining our URAC PBM accreditation is a testament to our commitment to continuous quality improvement for clinical care and program operations,” said Tamé Jaco, vice president of quality for Magellan Rx. “Congratulations to our clinical and program staff for continuing to highlight our dedication to ensuring patient safety and improving outcomes.”

URAC relies on a multidisciplinary advisory group to guide standards development, establish benchmarks and inform revisions. This group includes payers, physicians, hospitals, its Board of Directors, URAC’s Standards Committees and other industry experts. The standards are then circulated for public comment and beta-tested before their release. This broad, inclusive process assures that URAC’s standards promote industry best practices.

URAC’s comprehensive standards and associated elements of performance are organized into four foundational focus areas across all accreditation and certification programs:

  • Risk management
  • Operations infrastructure
  • Performance monitoring and improvement
  • Consumer protection and empowerment

Streamlining more than 40 core standards into these focus areas makes the process more seamless and enables URAC to conduct accreditation evaluations more quickly and efficiently.

“We applaud Magellan Rx on its subsidiaries Magellan Rx Management, LLC and Magellan Pharmacy Solutions, Inc. achieving URAC accreditation. With this distinction, Magellan Rx demonstrates excellence in quality health care delivery and their commitment to ensuring patient safety,” said URAC President and CEO Shawn Griffin, M.D.

Related news

Press releases

April 11, 2024

Prime Therapeutics and Magellan Rx to present eight managed care pharmacy research studies at AMCP

Prime/MRx remains at the forefront of GLP-1 research, presenting weight loss studies at this year’s annual meeting

Press releases

March 13, 2024

Prime Therapeutics and Capital Rx Enter Into Transformative Strategic Alliance

Strategic alliance allows Prime to offer exclusive access to Capital Rx’s leading technology platform to achieve a higher standard of care, increase efficiency, improve experiences and provide the foundation for the next generation of integrated pharmacy care for the more than 50 million Americans served by Prime

Press releases

February 8, 2024

Magellan Rx Management, LLC earns URAC Accreditation in Health Utilization Management

Designation demonstrates highest level of commitment to quality health care